Drug Trial Radar · NCT05244057
A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients
Last checked: Nov 19, 2026Latest source record: Jul 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Aug 23, 2022
Primary completion
Jun 24, 2024
Study completion Jun 24, 2024
Sponsor
- Lead sponsor
- Shanghai HEP Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Shanghai Tong Ren Hospital; Shanghai East Hospital
- First posted
- Feb 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is designed to assess efficacy of a finitie treatment in Chronic Hepatitis B patients who had stable treatment of NAs for ≧ 2 years, which is compared hepalatide in combination with Pegylated Interferon + TAF with Pegylated Interferon +TAF. Subjects will be randomly assigned to the hepalatide or placebo groups , 15 subjects in each group . Subjects will receive hepalatide+Pegylated Interferon +TAF treatment for 48 weeks or placebo +PegylatedInterferon +TAF treatment for 48 weeks , Then, stopping hepalatide and Pegylate Interferon treatments and followed with further 8 weeks follow-up.
Conditions
- Chronic Hepatitis B
Interventions
HepalatideDrug
6.3mg, s.c., qd for 48 weeks
Placebo of HepalatideDrug
s.c., qd for 48 weeks
Tenofovir Alafenamide TabletsDrug
25mg, p.o., qd for 48 weeks
Pegylated Interferon alfa 2aDrug
90ug, s.c., qw for 48 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects with negative conversion of HBsAgTime frame: 56 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Tong Ren Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.